INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
RESPIRATORY
PULMONARY
Dr Keat Theng Chow
Roquette
CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY
Dr Keat Theng Chow and Susana Ecenarro explore three myths surrounding inhalation as a route of administration, clearing the way for a deeper understanding of one of pharma’s most exciting areas for innovation.
NASAL
Matthias Müller
Contexo
FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING
Matthias Müller details how a close collaboration between Contexo and a pharmaceutical manufacturer led to the rapid development of a novel nasal spray product, taking the project from prototyping to market within 14 months, shaving 10 months off the anticipated launch date.
INTERVIEW
Charlie Schumacher
Phillips Medisize
Interview: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Charlie Schumacher and Sandy Munro discuss Phillips Medisize’s progress on its integration of Vectura, covering aspects such as cultural alignment, technical innovation and the evolving role of CDMOs in the inhalation landscape.
INDUSTRIALISATION
Nathan Sowder
Parker O-Ring & Engineered Seals Division
ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET
Nathan Sowder discusses Parker O-Ring & Engineered Seals Division’s role and history in providing advanced elastomer seals and components to the drug delivery industry, with a particular emphasis on pressurised metered dose inhalers.
RESPIRATORY
Ross Errington
Bespak
FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT
Ross Errington introduces Bespak’s Holmes Chapel (UK) site, which is equipped to support device development programmes from early-stage formulation to large-scale manufacture.
RESPIRATORY
David Farrow
Aptar Pharma
ORBITAL: A NOVEL HIGH-PAYLOAD, MULTI-BREATH DPI POISED FOR CLINICAL ADVANCEMENT
David Farrow, Jonathan Mulpas and Solange Le Nuz discuss the patient-centric and data-driven development of Aptar Pharma’s Orbital dry powder inhaler platform, tracing its evolution from an initial concept to a clinically-ready device.
CONNECTIVITY
Edgar Hernan Cuevas Brun
HCmed Innovations
NAVIGATING THE REGULATORY PATHWAY FOR NEXT-GENERATION NEBULISERS IN COMBINATION WITH BIOLOGICS
Edgar Hernan Cuevas Brun discusses the role of nebulisers in delivering larger doses of fragile biologics, delving into the global regulatory landscape that must be understood in order to deliver these drugs on the market.
PULMONARY
Dr Nicolas Buchmann
Resyca
ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY
Dr Nicolas Buchmann and Bernhard Müllinger, discuss the capabilities of soft mist inhalers in terms of usability for patients, sustainability, compatibility with biologics and cost-effective delivery, showcasing these advantages in Resyca’s Pre-Filled Syringe Inhaler (PFSI).
PULMONARY
Dr Gunilla Petersson
Nanoform
EXPANDING OPPORTUNITIES FOR INHALED DRUG DELIVERY
Dr Gunilla Petersson considers the challenges associated with efficiently delivering drugs to the lungs and the potential of nanoparticle-based formulations to achieve high lung deposition of small molecules and biologics, using gentle particle processing techniques that enable the delivery of sensitive drugs.
SUSTAINABILITY
Andy Burns
Kindeva
A BREATH OF FRESH AIR: PHARMA’S PUSH FOR SUSTAINABLE pMDIs
Andy Burns considers the driving factors for the transition to more sustainable propellants, as well as explaining the benefits and challenges of these next-generation propellants in terms of compatibility, performance, safety and global warming potential.
SUSTAINABILITY
Simon Gardner
Bespak
SCALING LOW-CARBON pMDI PRODUCTION WITHOUT DISRUPTING PATIENT ACCESS
Simon Gardner looks at how the pharmaceutical industry is scaling up production of low-carbon pressurised metered dose inhalers to cut emissions without disrupting patient care. The article considers the challenges faced by the industry, as well as the role of CDMOs in creating sustainable, scalable solutions.
INDUSTRIALISATION
Dr Carsten Köhler
BBS Automation
INFLUENCE OF MACHINE CONCEPTS ON OVERALL EQUIPMENT EFFECTIVENESS
Carsten Köhler provides an overview of the key metrics that contribute to overall equipment effectiveness for manufacturing drug delivery devices, detailing some of the options available when considering large-scale, high-volume manufacture.
INDUSTRIALISATION
Louise Righton
Bespak
SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN
Louise Righton examines the potential for reducing emissions across the pMDI supply chain, considering the localisation of suppliers to shorten supply chains as well as strong partnerships for developing novel, low-carbon alternatives to current high-emission pMDI manufacturing processes.
INTERVIEW
Brian Thompson
Phillips Medisize
Interview: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson discuss Phillips Medisize’s expanded capabilities as a result of its recent acquisition of Vectura, bringing extensive expertise and experience in the inhalation sector within the global CDMO. The discussion covers how Phillips Medisize organises its global operations, the opportunities that the acquisition of Vectura represents and where the company goes next.
INDUSTRIALISATION
Dr Steve Badelt
BlueRidge Life Sciences
CRITICAL LESSONS LEARNED: STRATEGIC PLANNING FOR DRUG DELIVERY SYSTEMS
Dr Steve Badelt of Suttons Creek, a BlueRidge Life Sciences company, discusses how the differing cultures and mindsets common to drug development and device design need to be brought together to achieve a smooth and successful combination product development programme, and explores some best practices for achieving optimal outcomes.
INTERVIEW
Chris Baron
Aptar Pharma
The Transition to Lower-Global-Warming-Potential Propellants in pMDIs
Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO
2
footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.
PULMONARY
Jonathan Mulpas
Aptar Pharma
THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS
Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.
EXPERT VIEW
Dr Heather Jameson
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.
EXPERT VIEW
Kamaal de Silva
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.
PULMONARY
Dr Clair Brooks
Copley Scientific
DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES
Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.
PULMONARY
Dr Alan Watts
Catalent Pharma Solutions
MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION
Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.
RESPIRATORY
Dr Philippe Rogueda
Merxin Ltd
TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?
Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.
NASAL
Sophie Conte
Nemera
NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING
Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.
EXPERT VIEW
Eric Kaneps
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.
Prev
1
2
3
4
…
21
Next
Top
